A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions: DRUG: Giredestrant|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Tamoxifen|DRUG: Everolimus|DRUG: LHRH Agonist|DRUG: Dexamethasone Mouth Rinse
Sponsor: Genentech, Inc.